The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. Check out the current price ...
As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...
Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...
・Retail traders ranked Novo Nordisk as the strongest long-term obesity play in a 1,100-vote poll. ・Users pointed to emerging ...
Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...
Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. It plunged to a low of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback